<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="pcmr13198" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pigment Cell Melanoma Res</journal-id><journal-id journal-id-type="iso-abbrev">Pigment Cell Melanoma Res</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1755-148X</journal-id><journal-id journal-id-type="publisher-id">PCMR</journal-id><journal-title-group><journal-title>Pigment Cell &#x00026; Melanoma Research</journal-title></journal-title-group><issn pub-type="ppub">1755-1471</issn><issn pub-type="epub">1755-148X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39344744</article-id><article-id pub-id-type="pmc">PMC11681845</article-id>
<article-id pub-id-type="doi">10.1111/pcmr.13198</article-id><article-id pub-id-type="publisher-id">PCMR13198</article-id><article-id pub-id-type="other">24-SC-110.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Short Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Pathogenic Germline Variants in Uveal Melanoma Driver and <styled-content style="fixed-case" toggle="no">BAP1</styled-content>&#x02010;Associated Genes in Finnish Patients with Uveal Melanoma</article-title></title-group><contrib-group><contrib id="pcmr13198-cr-0001" contrib-type="author" corresp="yes"><name><surname>Repo</surname><given-names>Pauliina E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9257-9376</contrib-id><xref rid="pcmr13198-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pcmr13198-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>pauliina.e.repo@helsinki.fi</email></address></contrib><contrib id="pcmr13198-cr-0002" contrib-type="author"><name><surname>Jakkula</surname><given-names>Eveliina</given-names></name><xref rid="pcmr13198-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="pcmr13198-cr-0003" contrib-type="author"><name><surname>Hiltunen</surname><given-names>Juho</given-names></name><xref rid="pcmr13198-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcmr13198-cr-0004" contrib-type="author"><name><surname>Putkuri</surname><given-names>Heidi</given-names></name><xref rid="pcmr13198-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcmr13198-cr-0005" contrib-type="author"><name><surname>Staskiewicz&#x02010;Tuikkanen</surname><given-names>Aleksandra</given-names></name><xref rid="pcmr13198-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcmr13198-cr-0006" contrib-type="author"><name><surname>J&#x000e4;rvinen</surname><given-names>Reetta&#x02010;Stiina</given-names></name><xref rid="pcmr13198-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcmr13198-cr-0007" contrib-type="author"><name><surname>T&#x000e4;ll</surname><given-names>Martin</given-names></name><xref rid="pcmr13198-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr13198-cr-0008" contrib-type="author"><name><surname>Raivio</surname><given-names>Virpi</given-names></name><xref rid="pcmr13198-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr13198-cr-0009" contrib-type="author"><name><surname>Al&#x02010;Jamal</surname><given-names>Rana'a T.</given-names></name><xref rid="pcmr13198-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr13198-cr-0010" contrib-type="author"><name><surname>Kivel&#x000e4;</surname><given-names>Tero T.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1198-4394</contrib-id><xref rid="pcmr13198-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr13198-cr-0011" contrib-type="author"><name><surname>Turunen</surname><given-names>Joni A.</given-names></name><xref rid="pcmr13198-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pcmr13198-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="pcmr13198-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Eye Genetics Group, Folkh&#x000e4;lsan Research Center, Biomedicum Helsinki</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><aff id="pcmr13198-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Ocular Oncology Service, Department of Ophthalmology</named-content>
<institution>University of Helsinki and Helsinki University Hospital</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><aff id="pcmr13198-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Genetics</named-content>
<institution>University of Helsinki and Helsinki University Hospital</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><aff id="pcmr13198-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Ophthalmic Genetics and Rare eye Diseases Service, Department of Ophthalmology</named-content>
<institution>University of Helsinki and Helsinki University Hospital</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Pauliina E. Repo (<email>pauliina.e.repo@helsinki.fi</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><volume>38</volume><issue seq="180">1</issue><issue-id pub-id-type="doi">10.1111/pcmr.v38.1</issue-id><elocation-id>e13198</elocation-id><history>
<date date-type="rev-recd"><day>02</day><month>9</month><year>2024</year></date>
<date date-type="received"><day>27</day><month>6</month><year>2024</year></date>
<date date-type="accepted"><day>02</day><month>9</month><year>2024</year></date>
</history><permissions><!--Copyright &#x000a9; 2025 John Wiley & Sons A/S--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">Pigment Cell &#x00026; Melanoma Research</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PCMR-38-0.pdf"/><abstract><title>ABSTRACT</title><p>Uveal melanoma (UM) is a rare yet aggressive eye cancer causing over 50% mortality from metastasis. Familial UM, amounting to 1%&#x02013;6% of patients in Finland and the United States, mostly lack identified genetic cause, while 8% show associations with other cancer syndromes. We searched novel genetic associations for predisposition to UM, additional to already studied <italic toggle="no">BAP1</italic> and <italic toggle="no">MBD4</italic>, by using targeted amplicon sequencing of 19 genes associated with UM, BAP1, or renal cell carcinoma in 270 consecutively enrolled Finnish patients with UM. Key UM drivers <italic toggle="no">GNAQ</italic>, <italic toggle="no">GNA11</italic>, <italic toggle="no">CYSLTR2</italic>, <italic toggle="no">PLCB4</italic>, <italic toggle="no">EIF1AX</italic>, and <italic toggle="no">SF3B1</italic> lacked pathogenic germline variants. One patient carried the pathogenic <italic toggle="no">BRCA1</italic> variant c.3626del p.(Leu1209*), and one harbored a novel truncating <italic toggle="no">MET</italic> variant c.252C&#x02009;&#x0003e;&#x02009;G p.(Tyr84*), classified as likely pathogenic. <italic toggle="no">FLCN</italic> and <italic toggle="no">BRCA2</italic>, previously identified with pathogenic variants in patients with UM, did not have such variants in our cohort. Two patients were heterozygous for a pathogenic recessive <italic toggle="no">BLM</italic> variant c.2824&#x02010;2A&#x02009;&#x0003e;&#x02009;T. None of the carriers of identified variants had familial UM. We identified <italic toggle="no">BRCA1</italic> and <italic toggle="no">MET</italic> as genes with pathogenic germline variants in Finnish UM patients, each with a frequency of 0.4% (95% confidence interval, 0&#x02013;2).</p></abstract><abstract abstract-type="graphical"><p>We enrolled a consecutive cohort of 270 Finnish patients with uveal melanoma (UM) and analyzed them for pathogenic germline variants in 19 genes associated with UM, BAP1, or renal cell carcinoma (RCC). One patient carried the pathogenic <italic toggle="yes">BRCA1</italic> variant c.3626del; p.(Leu1209*), while another had a likely pathogenic <italic toggle="yes">MET</italic> variant c.252C&#x0003e;G; p.(Tyr84*). Additionally, two patients were identified as heterozygous for the recessive pathogenic <italic toggle="yes">BLM</italic> variant c.2824&#x02010;2A&#x0003e;T.<boxed-text position="anchor" content-type="graphic" id="pcmr13198-blkfxd-0801"><graphic xlink:href="PCMR-38-0-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pcmr13198-kwd-0001">BAP1</kwd><kwd id="pcmr13198-kwd-0002">cancer syndrome</kwd><kwd id="pcmr13198-kwd-0003">genetic predisposition</kwd><kwd id="pcmr13198-kwd-0004">uveal melanoma</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Helsinki University Hospital Research Fund</funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Silm&#x000e4;&#x02010; ja kudospankkis&#x000e4;&#x000e4;ti&#x000f6;
</institution><institution-id institution-id-type="doi">10.13039/501100013510</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Mary och Georg C. Ehrnrooths Stiftelse
</institution><institution-id institution-id-type="doi">10.13039/100015738</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Evald ja Hilda Nissin S&#x000e4;&#x000e4;ti&#x000f6;
</institution><institution-id institution-id-type="doi">10.13039/501100011905</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Silm&#x000e4;s&#x000e4;&#x000e4;ti&#x000f6;
</institution><institution-id institution-id-type="doi">10.13039/501100013511</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Sy&#x000f6;p&#x000e4;s&#x000e4;&#x000e4;ti&#x000f6;
</institution><institution-id institution-id-type="doi">10.13039/501100010711</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="9"/><word-count count="6700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="pcmr13198-ntgp-0001"><fn fn-type="funding" id="pcmr13198-note-0001"><p>
<bold>Funding:</bold> This work was funded by the Helsinki University Hospital Research Fund [grant number TYH2023312 to TTK and TYH2023338 to JAT]; The Eye and Tissue Bank Foundation, Helsinki, Finland;&#x02009;Mary and Georg C. Ehrnrooth Foundation, Helsinki, Finland; Evald and Hilda Nissi Foundation, Vaasa, Finland; The Eye Foundation, Helsinki, Finland; and The Cancer Foundation, Helsinki, Finland.</p></fn><fn fn-type="equal" id="pcmr13198-note-0002"><p>Tero T. Kivel&#x000e4; and Joni A. Turunen contributed equally as co&#x02010;last authors.</p></fn></fn-group></notes></front><body id="pcmr13198-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="pcmr13198-blkfxd-0001"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="pcmr13198-list-0001"><list-item id="pcmr13198-li-0001"><p>Taken together with our previous studies, a broader germline analysis of 270 consecutively enrolled Finnish patients with uveal melanoma (UM) reaffirms <italic toggle="yes">BAP1</italic> as the primary contributor to genetic predisposition to UM.</p></list-item><list-item id="pcmr13198-li-0002"><p>No pathogenic germline variants in other UM drivers were identified.</p></list-item><list-item id="pcmr13198-li-0003"><p>Among previously reported genes, a pathogenic <italic toggle="yes">BRCA1</italic> variant was identified in one patient in our cohort, whereas no such variants were found in <italic toggle="yes">BRCA2</italic> or <italic toggle="yes">FLCN</italic>.</p></list-item><list-item id="pcmr13198-li-0004"><p>A likely pathogenic <italic toggle="yes">MET</italic> variant warrants further investigation. No pathogenic germline variants were found in eight familial UM patients, highlighting need for continued research.</p></list-item></list>
</p></boxed-text>
</p><p>Uveal melanoma (UM), the most prevalent primary intraocular cancer in adults, originates from melanocytes of the choroid, ciliary body, or iris, typically because of one of a few well&#x02010;established somatic driver events. Approximately 90% of tumors exhibit mutually exclusive mutations in the G&#x02010;protein pathway genes <italic toggle="yes">GNAQ</italic> or <italic toggle="yes">GNA11</italic>, while 4%&#x02013;5% harbor mutations in their downstream effector <italic toggle="yes">PLCB4</italic>, and 2% in <italic toggle="yes">CYSLTR2</italic> coding for an upstream G&#x02010;protein&#x02010;coupled receptor (Field et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0012" ref-type="bibr">2018</xref>; Johansson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0023" ref-type="bibr">2016</xref>; Moore et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0036" ref-type="bibr">2016</xref>; Robertson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0048" ref-type="bibr">2017</xref>; Shain et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0055" ref-type="bibr">2019</xref>; Van Raamsdonk et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0063" ref-type="bibr">2009</xref>, <xref rid="pcmr13198-bib-0064" ref-type="bibr">2010</xref>). Subsequent mutations, also typically mutually exclusive, occur in <italic toggle="yes">BAP1</italic>, <italic toggle="yes">EIF1AX</italic>, and <italic toggle="yes">SF3B1</italic> in 50%, 14%&#x02013;22% and 11%&#x02013;19% of tumors, respectively, correlating with high, low, and intermediate risk of metastasis (Field et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0012" ref-type="bibr">2018</xref>; Johansson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0024" ref-type="bibr">2020</xref>; Robertson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0048" ref-type="bibr">2017</xref>; Rodrigues et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0050" ref-type="bibr">2019</xref>; Royer&#x02010;Bertrand et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0052" ref-type="bibr">2016</xref>; Shain et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0055" ref-type="bibr">2019</xref>). <italic toggle="yes">MBD4</italic> loss is observed in up to 4% of primary UM in France, contributing to a distinct hypermutated tumor phenotype (Derrien et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0010" ref-type="bibr">2021</xref>; Johansson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0025" ref-type="bibr">2019</xref>; Rodrigues et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0051" ref-type="bibr">2018</xref>; Saint&#x02010;Ghislain et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0053" ref-type="bibr">2022</xref>).</p><p>
<italic toggle="yes">MBD4</italic> and, especially, <italic toggle="yes">BAP1</italic> are also associated with inherited UM predisposition. Pathogenic germline <italic toggle="yes">BAP1</italic> variants are identified in ~2% of all patients and in 20%&#x02013;25% of those with familial UM (Gupta et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0015" ref-type="bibr">2015</xref>; Pilarski et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0043" ref-type="bibr">1993</xref>; Rai et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0044" ref-type="bibr">2017</xref>; Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>; Turunen et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0062" ref-type="bibr">2016</xref>). UM is one core tumor in dominantly inherited BAP1 tumor predisposition syndrome (BAP1&#x02010;TPDS, OMIM 614327), along with mesothelioma, cutaneous melanoma, and clear cell renal cell carcinoma (Carbone et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0006" ref-type="bibr">2022</xref>). Deleterious germline <italic toggle="yes">MBD4</italic> variants cause recessive tumor predisposition syndrome 2 (TPDS2; OMIM 619975), linked especially to acute myeloid leukemia, colorectal cancer, and UM (Palles et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0041" ref-type="bibr">2022</xref>). Heterozygous carriers of these variants are estimated to have a 9.15&#x02010;fold higher incidence of UM compared to the general French population (Derrien et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0010" ref-type="bibr">2021</xref>). Additionally, patients with UM have been identified with pathogenic germline variants in 15 other cancer&#x02010;associated genes (Abdel&#x02010;Rahman et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0003" ref-type="bibr">2020</xref>; Cruz et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0007" ref-type="bibr">2011</xref>; Fontcuberta et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0013" ref-type="bibr">2011</xref>; Hajkova et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0016" ref-type="bibr">2018</xref>; Hearle et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0018" ref-type="bibr">2003</xref>; Huang et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0021" ref-type="bibr">2018</xref>; Iscovich et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0022" ref-type="bibr">2002</xref>; Kannengiesser et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0026" ref-type="bibr">2003</xref>; Lobo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0032" ref-type="bibr">2017</xref>; Nathan et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0038" ref-type="bibr">2021</xref>; Sinilnikova et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0057" ref-type="bibr">1999</xref>).</p><p>Pathogenic variants in UM tumorigenesis and BAP1&#x02010;associated genes result in diverse outcomes depending on whether they are somatic, inherited, or <italic toggle="yes">de novo</italic>, with the extent of possible mosaicism further shaping the phenotype. <italic toggle="yes">De novo</italic> missense variants in <italic toggle="yes">BAP1</italic> are associated with neurodevelopmental Kury&#x02013;Isidor syndrome, with assumed cancer predisposition similar to BAP1&#x02010;TPDS (Kury et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0030" ref-type="bibr">2022</xref>). Kury&#x02013;Isidor syndrome shares features with Bohring&#x02013;Opitz, Shashi&#x02013;Pena and Bainbridg&#x02013;eRopers syndromes, caused by mosaic or <italic toggle="yes">de novo</italic> pathogenic variants in <italic toggle="yes">ASXL1</italic>/<italic toggle="yes">2</italic>/<italic toggle="yes">3</italic> genes, with unclear cancer predisposition (Cuddapah et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0008" ref-type="bibr">2021</xref>). ASXL proteins interact with BAP1 and are somatically altered particularly in hematological cancers (Micol and Abdel&#x02010;Wahab&#x000a0;<xref rid="pcmr13198-bib-0033" ref-type="bibr">2016</xref>). Mosaicism for pathogenic <italic toggle="yes">GNAQ</italic> variants, and rarely for <italic toggle="yes">GNA11</italic>, causes vascular abnormalities ranging from port&#x02010;wine birthmarks to Sturge&#x02013;Weber syndrome, with glaucoma and neurological involvement that depend on mosaicism extent (Dompmartin et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0011" ref-type="bibr">2022</xref>; Van Trigt, Kelly, and Hughes&#x000a0;<xref rid="pcmr13198-bib-0065" ref-type="bibr">2022</xref>). Germline pathogenic variants in <italic toggle="yes">GNA11</italic> are also associated with dominantly inherited hypo&#x02010; and hypercalcemia (Howles et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0020" ref-type="bibr">2023</xref>), while those in <italic toggle="yes">PLCB4</italic> with dominantly and recessively inherited auriculocondylar syndrome (Nabil et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0037" ref-type="bibr">2020</xref>). To our knowledge, no cancer phenotype is reported with <italic toggle="yes">GNAQ</italic> and <italic toggle="yes">GNA11</italic> associated Sturge&#x02013;Weber syndrome, <italic toggle="yes">GNA11</italic> associated hypo&#x02010; or hypercalcemia, or <italic toggle="yes">PLCB4</italic> associated auriculocondylar syndrome, although the function of these genes is somatically altered in uveal melanomas. <italic toggle="yes">CYSLTR2</italic>, <italic toggle="yes">EIF1AX</italic>, and <italic toggle="yes">SF3B1</italic>, have not been associated with inherited conditions so far, although the latter is frequently altered in myeloid malignancies in addition to UMs.</p><p>The genetic basis of familial UM (FUM) remains unresolved in 75%&#x02013;80% of patients (Abdel&#x02010;Rahman et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0003" ref-type="bibr">2020</xref>; Rai et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0044" ref-type="bibr">2017</xref>; Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>). Consequently, genes other than <italic toggle="yes">BAP1</italic> and <italic toggle="yes">MBD4</italic> likely predispose to UM. An additional 8% might emerge in families with other cancer syndromes such as breast&#x02010;ovarian cancer syndrome, familial melanoma, or Lynch syndrome (Abdel&#x02010;Rahman et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0001" ref-type="bibr">2010</xref>). Further, renal cell carcinoma (RCC) has been hypothesized to have genetic similarities with UM (Singla&#x000a0;<xref rid="pcmr13198-bib-0056" ref-type="bibr">2020</xref>). To elucidate additional genetic factors that may predispose to UM, we conducted germline targeted amplicon sequencing of 19 genes in a consecutive cohort of patients with UM, originating from Finland, a country from Northern Europe, a region with a higher than average incidence of UM in Europe (Kivel&#x000e4;&#x000a0;<xref rid="pcmr13198-bib-0028" ref-type="bibr">2014</xref>; Virgili et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0066" ref-type="bibr">2007</xref>). We analyzed pathogenic germline variants within coding regions of six genes associated with UM tumorigenesis, seven linked to BAP1 functions, and seven confirmed or candidate genes for RCC, a cancer that in our service was the most common nonocular malignancy associated with BAP1&#x02010;TPDS, the co&#x02010;occurrence of which with UM we at the time also explored in patients outside the present, consecutive series of UM. The latter included three genes previously linked to UM in isolated patients, of which BRCA1 is known to interact with BAP1 (Figure&#x000a0;<xref rid="pcmr13198-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><p>We enrolled 270 (52%) of the 521 Finnish patients consecutively diagnosed with UM at the Ocular Oncology Service, Helsinki University Hospital, a national referral center, between 2010 and 2017, who were willing to participate and whose samples were available at the time of the sequencing. All patients had been previously analyzed for pathogenic germline variants in <italic toggle="yes">BAP1</italic> and <italic toggle="yes">MBD4</italic> (Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0045" ref-type="bibr">2020</xref>, <xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>; Turunen et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0062" ref-type="bibr">2016</xref>). Eight patients who were pathogenic variant carriers were excluded from the present study (8 with <italic toggle="yes">BAP1</italic>, none carried <italic toggle="yes">MBD4</italic>). The patients were queried for history of previous cancers at the time of diagnosis, and subsequently during annual follow&#x02010;up visits. Reported nonocular cancers were verified from patient records. Detailed patient characteristics of all eligible patients is reported in Repo et&#x000a0;al.&#x000a0;(<xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>) Table&#x000a0;S1. The project was approved by the institutional review board of the Hospital Region of Helsinki and Uusimaa on June 11, 2012, and it followed the tenets of the Declaration of Helsinki.</p><p>Genomic DNA was extracted from peripheral whole blood using standard methods. The targeted genes were selected based on the literature (Johansson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0023" ref-type="bibr">2016</xref>; Moore et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0036" ref-type="bibr">2016</xref>; Royer&#x02010;Bertrand et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0052" ref-type="bibr">2016</xref>; Van Raamsdonk et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0063" ref-type="bibr">2009</xref>; Van Raamsdonk et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0064" ref-type="bibr">2010</xref>), STRING (Szklarczyk et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0059" ref-type="bibr">2019</xref>) and the Cancer Gene Census databases (Sondka et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0058" ref-type="bibr">2018</xref>). The sequencing probes were designed with DesignStudio Sequencing Assay Designer (Illumina, San Diego, CA). Library preparation was done using TruSeq Custom Amplicon kit v1.5 (Illumina), and samples were sequenced with HiSeq 2500 (Illumina) at the Institute for Molecular Medicine Finland (FIMM, Helsinki, Finland). The read alignment to Genome Reference Consortium Human Build 37 (GRCh37) has been described previously (Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>). We included only variants with a read depth of at least 10 and a variant allele frequency (VAF) of 30% or higher. The remaining variants were annotated with Annotate Variation (ANNOVAR) (Wang, Li, and Hakonarson&#x000a0;<xref rid="pcmr13198-bib-0067" ref-type="bibr">2010</xref>). All variants reported as pathogenic or likely pathogenic in ClinVar were included in further analysis. Additionally, nonsynonymous exonic and splicing region (&#x000b1;&#x02009;2&#x02009;bp) variants with minor allele frequency in gnomAD v2.1.1 (Karczewski et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0027" ref-type="bibr">2020</xref>) &#x0003c; 0.001 were analyzed if they received deleterious MetaRNN (Li et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0031" ref-type="bibr">2022</xref>) prediction and were not reported as benign or likely benign. VarSome (Kopanos et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0029" ref-type="bibr">2019</xref>) was utilized to assign The American College of Medical Genetics and Genomics (ACMG) classification to the remaining variants (Richards et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0047" ref-type="bibr">2015</xref>). Pathogenic and likely pathogenic variants and variants of unknown significance (VUS) were visualized with Integrative Genomics Viewer (IGV) (Robinson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0049" ref-type="bibr">2011</xref>) and looked up from gnomAD v.4.1.0. The Cancer Genome Atlas (TCGA) database at <ext-link xlink:href="http://www.cancer.gov/tcga" ext-link-type="uri">www.cancer.gov/tcga</ext-link>, and the Catalogue of Somatic Mutations in Cancer (COSMIC) at <ext-link xlink:href="https://cancer.sanger.ac.uk/cosmic" ext-link-type="uri">https://cancer.sanger.ac.uk/cosmic</ext-link> were utilized when relevant. Carrier frequencies with 95% confidence intervals (CI) were calculated using the modified Wald method. Two&#x02010;sided Fisher's exact test was using to probe association between carrier status and UM with RStudio 4.1.0.</p><p>The median age at diagnosis of UM was 64&#x02009;years (range, 15&#x02013;89; Table&#x000a0;<xref rid="pcmr13198-tbl-0001" ref-type="table">1</xref>). Eight patients (3%) from seven families reported a relative with UM. One family included a pair of cousins, both enrolled, while the rest had one first&#x02010;degree relative (1 family), cousin (2 families) or a more distant relative (3 families) with UM. Two patients with FUM also had clear cell type RCC and one of them had cutaneous melanoma as third cancer. Additional to their UM, 14 patients have had prostate cancer, 11 breast cancer, and 6 RCC, and one patient a benign renal oncocytoma. In total, 53 (20%; 95% CI, 15&#x02013;25) of the enrolled patients had a nonocular primary malignancy, seven of whom had 2 and one had 3 such cancers (Table&#x000a0;<xref rid="pcmr13198-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="pcmr13198-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Characteristics of 270 eligible Finnish patients with primary uveal melanoma at the time of diagnosis and their disease outcome.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1"/></tr></thead><tbody valign="top"><tr><td align="left" colspan="2" valign="top" rowspan="1">Gender, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">141 (52)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">129 (48)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median age, years (range)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (15&#x02013;89)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Age, years</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">10&#x02013;29</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">30&#x02013;39</td><td align="center" valign="top" rowspan="1" colspan="1">8 (3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">40&#x02013;49</td><td align="center" valign="top" rowspan="1" colspan="1">27 (10)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">50&#x02013;59</td><td align="center" valign="top" rowspan="1" colspan="1">57 (21)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">60&#x02013;69</td><td align="center" valign="top" rowspan="1" colspan="1">103 (38)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">70&#x02013;79</td><td align="center" valign="top" rowspan="1" colspan="1">50 (19)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">80&#x02013;99</td><td align="center" valign="top" rowspan="1" colspan="1">21 (8)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Younger than 45&#x02009;years</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">249 (92)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">21 (8)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Family history of uveal melanoma, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">262 (97)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">8 (3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median thickness, mm (range)</td><td align="center" valign="top" rowspan="1" colspan="1">3.9 (0.2&#x02013;19.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median largest basal diameter, mm (range)</td><td align="center" valign="top" rowspan="1" colspan="1">11.8 (1.2&#x02013;26.0)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Location, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Iris only</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ciliary body and choroid</td><td align="center" valign="top" rowspan="1" colspan="1">56 (21)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Choroid only</td><td align="center" valign="top" rowspan="1" colspan="1">205 (76)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Extraocular extension, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">261 (97)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">TNM category, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T1</td><td align="center" valign="top" rowspan="1" colspan="1">98 (36)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T2</td><td align="center" valign="top" rowspan="1" colspan="1">77 (29)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T3</td><td align="center" valign="top" rowspan="1" colspan="1">67 (25)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T4</td><td align="center" valign="top" rowspan="1" colspan="1">28 (10)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">TNM stage, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">89 (33)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIA</td><td align="center" valign="top" rowspan="1" colspan="1">71 (26)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIB</td><td align="center" valign="top" rowspan="1" colspan="1">45 (17)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIIA</td><td align="center" valign="top" rowspan="1" colspan="1">38 (14)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIIB</td><td align="center" valign="top" rowspan="1" colspan="1">12 (4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIIC</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IV</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not defined<xref rid="pcmr13198-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Number of nonocular cancers, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">None</td><td align="center" valign="top" rowspan="1" colspan="1">216 (80)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">One</td><td align="center" valign="top" rowspan="1" colspan="1">46 (17)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Two</td><td align="center" valign="top" rowspan="1" colspan="1">7 (3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Three</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Type of nonocular cancer, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prostate carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">14 (5/10)<xref rid="pcmr13198-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">12 (4/9)<xref rid="pcmr13198-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Renal cell carcinoma<xref rid="pcmr13198-note-0007" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intestinal carcinoma<xref rid="pcmr13198-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cutaneous basal cell carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cutaneous squamous cell carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">2 (&#x0003c;1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pancreatic adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Neuroendocrine small cell pulmonary carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Uterine carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1/&#x0003c;1)<xref rid="pcmr13198-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Adenocarcinoma, uncertain primary</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Metastatic uveal melanoma, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">201 (73)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">73 (27)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Survival status, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alive</td><td align="center" valign="top" rowspan="1" colspan="1">166 (61)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Dead of metastatic uveal melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">70 (26)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Dead of nonocular cancer</td><td align="center" valign="top" rowspan="1" colspan="1">16 (6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Dead of nonmalignant disease</td><td align="center" valign="top" rowspan="1" colspan="1">18 (7)</td></tr></tbody></table><table-wrap-foot id="pcmr13198-ntgp-0002"><fn id="pcmr13198-note-0003"><p>Abbreviation: TNM, Tumor, Node, Metastasis classification, 8th edition.</p></fn><fn id="pcmr13198-note-0004"><label>
<sup>a</sup>
</label><p>Stage is not defined for iris melanoma.</p></fn><fn id="pcmr13198-note-0005"><label>
<sup>b</sup>
</label><p>All/male patients.</p></fn><fn id="pcmr13198-note-0006"><label>
<sup>c</sup>
</label><p>All/female patients.</p></fn><fn id="pcmr13198-note-0007"><label>
<sup>d</sup>
</label><p>Clear cell type (4), mixed clear cell and papillary type (1), and papillary type (1).</p></fn><fn id="pcmr13198-note-0008"><label>
<sup>e</sup>
</label><p>Adenocarcinoma of the colon (2), rectum (1), sigma (1), and appendix (1).</p></fn></table-wrap-foot></table-wrap><p>Dominant cancer&#x02010;associated pathogenic and likely pathogenic variants were identified in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">MET</italic>, and two patients were carriers of recessive pathogenic <italic toggle="yes">BLM</italic> variants. The pathogenic <italic toggle="yes">BRCA1</italic> variant c.3626del p.(Leu1209*), associated with dominant familial breast&#x02010;ovarian cancer (Sarantaus et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0054" ref-type="bibr">2000</xref>), was detected in a male diagnosed with a T2b, Stage IIB, UM at the age of 54, without family history of UM (Table&#x000a0;<xref rid="pcmr13198-tbl-0002" ref-type="table">2</xref>, Figure&#x000a0;<xref rid="pcmr13198-supitem-0002" ref-type="supplementary-material">S2</xref>). The overall allele frequency of the variant is 4.0&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup> in gnomAD v.2.1.1, with no Finnish carriers, and 1.9&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup> in gnomAD v.4.1.0, with a carrier frequency of 1 in 10,673 Finns (0.0094%, 95% CI 1 in 5,000 to 1 in 19). In the Finnish UM cohort, the carrier frequency is 1 in 270 (0.37%, 95% CI 0.009 to 2.05), and not significantly different from the frequency of probable loss&#x02010;of&#x02010;function (pLOF) <italic toggle="yes">BRCA1</italic> variant carriers observed in Finns in general (Table&#x000a0;<xref rid="pcmr13198-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="pcmr13198-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Rare pathogenic and likely pathogenic variants and variants of unknown significance (VUS) in 270 Finnish patients with primary uveal melanoma (UM). Age refers to the age of the patient at the time of UM diagnosis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene (transcript)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Variant</th><th align="center" valign="bottom" rowspan="1" colspan="1">ACMG Classification</th><th align="center" valign="bottom" rowspan="1" colspan="1">ClinVar variation ID</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gene Associated malignancy risk</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sex/age</th><th align="center" valign="bottom" rowspan="1" colspan="1">TNM</th><th align="center" valign="bottom" rowspan="1" colspan="1">Site</th><th align="center" valign="bottom" rowspan="1" colspan="1">Height/LBD mm</th><th align="center" valign="bottom" rowspan="1" colspan="1">Status Metastases</th><th align="center" valign="bottom" rowspan="1" colspan="1">FUP years</th><th align="center" valign="bottom" rowspan="1" colspan="1">Nonocular cancers</th><th align="center" valign="bottom" rowspan="1" colspan="1">Familial UM</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<italic toggle="yes">BRCA1</italic>
</p>
<p>(NM_007294.4)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>c.3626del</p>
<p>Leu1209*</p>
<p>rs80357571</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Pathogenic</p>
<p>(PVS1, PP5, PM2)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">54,943</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>AD Familial breast&#x02010;ovarian cancer (OMIM 604370), high risk</p>
<p>AD Pancreatic adenocarcinoma (OMIM 614320), moderate risk</p>
<p>AR Fanconi anemia, complementation group S (OMIM 617883), high risk</p>
<p>other malignancies, risk/association pending confirmation</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">M/54</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>T2b</p>
<p>Stage IIB</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Choroid</td><td align="center" valign="top" rowspan="1" colspan="1">5.4/12.7</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dead</p>
<p>No</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">6&#x02009;years 1&#x02009;months</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>No</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<italic toggle="yes">MET</italic>
</p>
<p>(NM_000245.4)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>c.252C&#x02009;&#x0003e;&#x02009;G</p>
<p>Tyr84*</p>
<p>rs1584876265</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Likely Pathogenic</p>
<p>(PVS1, PM2)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">AD Papillary renal cell carcinoma&#x02010;1 (OMIM 605074), high risk</td><td align="center" valign="top" rowspan="1" colspan="1">M/54</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>T2a</p>
<p>Stage IIA</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Choroid</td><td align="center" valign="top" rowspan="1" colspan="1">5.0/10.8</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Alive</p>
<p>No</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">10&#x02009;years 2months</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">
<p>
<italic toggle="yes">BLM</italic>
</p>
<p>(NM_000057.4)</p>
</td><td align="center" rowspan="2" valign="top" colspan="1">
<p>c.2824&#x02010;2A&#x02009;&#x0003e;&#x02009;T</p>
<p>rs745538883</p>
</td><td align="center" rowspan="2" valign="top" colspan="1">
<p>Pathogenic</p>
<p>(PVS1, PM2, PP5)</p>
</td><td align="center" rowspan="2" valign="top" colspan="1">371,621</td><td align="center" rowspan="3" valign="top" colspan="1">
<p>AR Bloom syndrome (OMIM 210900, risk of various cancers at young age)</p>
<p>AD breast, mesothelioma, colorectal cancer, risk/association pending confirmation</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">M/45</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>T3a</p>
<p>Stage IIB</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Choroid</td><td align="center" valign="top" rowspan="1" colspan="1">10.6/11.2</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Alive</p>
<p>No</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">8&#x02009;years 10months</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>No</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">M/64</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>T4b</p>
<p>Stage IIIB</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Choroid</td><td align="center" valign="top" rowspan="1" colspan="1">12.0/18.2</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dead</p>
<p>Yes</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">2&#x02009;years 11months</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<p>c.2489C&#x02009;&#x0003e;&#x02009;T</p>
<p>Thr830Met</p>
<p>rs759545027</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>VUS</p>
<p>(PP3, PM2, BP1)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">1,337,765</td><td align="center" valign="top" rowspan="1" colspan="1">F/53</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>T1a</p>
<p>Stage I</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Choroid</td><td align="center" valign="top" rowspan="1" colspan="1">2.4/7.3</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Alive</p>
<p>No</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">10&#x02009;years 2months</td><td align="center" valign="top" rowspan="1" colspan="1">Breast cancer age 62&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr></tbody></table><table-wrap-foot id="pcmr13198-ntgp-0003"><fn id="pcmr13198-note-0009"><p>Abbreviations: ACMG, The American College of Medical Genetics and Genomics; AD, autosomal dominant; AR, autosomal recessive; BP1, missense variant in a gene for which primarily truncating variants are known to cause disease; F, female; FUP, follow&#x02010;up time; LBD, largest basal diameter; M, male; PM2, Absent or very rare from race&#x02010;matched controls gnomAD; PP3, multiple lines of computational evidence support a deleterious effect; PP5, reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation; PVS1, Null variant in a gene where loss of function is a known mechanism of disease; TNM, tumor, node, metastasis classification.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pcmr13198-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Frequency of pathogenic germline variant carriers in Finnish (FIN) patients with uveal melanoma (UM) compared to all probable loss&#x02010;of&#x02010;function (pLOF) variant carriers reported in gnomAD, by gene.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">UM patients</th><th align="center" valign="bottom" rowspan="1" colspan="1">pLOF gnomAD FIN<xref rid="pcmr13198-note-0011" ref-type="table-fn">*</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value (Two&#x02010;sided Fisher's exact test)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Odds ratio (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">BRCA1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1/270 (0.37%)</td><td align="center" valign="top" rowspan="1" colspan="1">18/32,026 (0.056%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">7 (95% CI 0&#x02013;42)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">BLM</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">2/270 (0.74%)</td><td align="center" valign="top" rowspan="1" colspan="1">27/32,026 (0.084%)</td><td align="center" valign="top" rowspan="1" colspan="1">p&#x02009;=&#x02009;0.024</td><td align="center" valign="top" rowspan="1" colspan="1">9 (95% CI 1&#x02013;35)</td></tr></tbody></table><table-wrap-foot id="pcmr13198-ntgp-0004"><fn id="pcmr13198-note-0010"><p>Abbreviation: CI, confidence intervals.</p></fn><fn id="pcmr13198-note-0011"><label>*</label><p>Documentation of gnomAD v.4.1.0 includes annotation of 32,026 Finnish individuals. No homozygous individuals for variants in either gene were represented in gnomAD v.4.1.0 FIN, and the number of carriers for all variants annotated as pLOF was extracted directly. Variants reported as benign, likely benign, or of uncertain significance (VUS) in ClinVar, or flagged with low confidence annotation, were excluded.</p></fn></table-wrap-foot></table-wrap><p>A truncating likely pathogenic <italic toggle="yes">MET</italic> variant c.252C&#x02009;&#x0003e;&#x02009;G, p.(Tyr84*) was identified in another male diagnosed with a T2a, Stage IIA, UM at the age of 54 (Table&#x000a0;<xref rid="pcmr13198-tbl-0002" ref-type="table">2</xref>, Figure&#x000a0;<xref rid="pcmr13198-supitem-0002" ref-type="supplementary-material">S2</xref>). Variants in the <italic toggle="yes">MET</italic> proto&#x02010;oncogene that are associated with RCC typically exhibit gain&#x02010;of&#x02010;function characteristics, resulting in increased MET protein levels or activity (Tovar and Graveel&#x000a0;<xref rid="pcmr13198-bib-0061" ref-type="bibr">2017</xref>). The patient had no history of any nonocular cancer, and no metastases were detected during follow&#x02010;up of over 10&#x02009;years. This variant is neither present in the general population according to gnomAD nor in the TCGA or COSMIC databases that list somatic variants in cancers. <italic toggle="yes">MET</italic> c.252C&#x02009;&#x0003e;&#x02009;G lacks evidence of gain&#x02010;of&#x02010;function properties and its association with cancer is uncertain.</p><p>The pathogenic recessive <italic toggle="yes">BLM</italic> splice site variant c.2824&#x02010;2A&#x02009;&#x0003e;&#x02009;T was found in heterozygous state in two males diagnosed with UM at ages 45 and 65, with Stage T3a, IIB, and Stage T4b, IIIB UM, respectively (carrier frequency, 2/270; 0.74%; 95% CI 0.090 to 2.65, Table&#x000a0;<xref rid="pcmr13198-tbl-0003" ref-type="table">3</xref>, Figure&#x000a0;<xref rid="pcmr13198-supitem-0002" ref-type="supplementary-material">S2</xref>). The older patient with a more advanced melanoma died of metastases after less than 3&#x02009;years whereas the other one is free of metastases after almost 9&#x02009;years, neither had nonocular cancers. The overall allele frequency of c.2824&#x02010;2A&#x02009;&#x0003e;&#x02009;T in gnomAD v.2.1.1 is 1.1&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup>, and 5.6&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup> in v.4.1.0 with three Finnish carriers, corresponding to 1 in 10,674 Finns (0.0094%, 95% CI 1 in 5,000 to 1 in 19). In our cohort, carriers of pathogenic germline <italic toggle="yes">BLM</italic> variants were more prevalent compared to individuals with pLOF <italic toggle="yes">BLM</italic> variants in the general Finnish population according to gnomAD v.4.1.0 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.024; odds ratio 9, 95% CI 1&#x02013;35, Fisher's exact test, Table&#x000a0;<xref rid="pcmr13198-tbl-0003" ref-type="table">3</xref>). Pathogenic germline <italic toggle="yes">BLM</italic> variants are associated with recessive Bloom syndrome, characterized by shorter stature, narrow face, skin rash, and early&#x02010;onset of various cancers, notably cutaneous squamous cell carcinoma, leukemia, lymphoma, and gastrointestinal tract cancer (Cunniff, Bassetti, and Ellis&#x000a0;<xref rid="pcmr13198-bib-0009" ref-type="bibr">2017</xref>).</p><p>Additionally, <italic toggle="yes">BLM</italic> c.2489C&#x02009;&#x0003e;&#x02009;T p.(Thr830Met) VUS was identified in a female with T1a, Stage I, UM at the age of 53&#x02009;years and breast cancer at the age of 62&#x02009;years (Table&#x000a0;<xref rid="pcmr13198-tbl-0002" ref-type="table">2</xref>, Figure&#x000a0;<xref rid="pcmr13198-supitem-0002" ref-type="supplementary-material">S2</xref>). Neither one has metastasized. The overall allele frequency of the VUS is 8.0&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup> in gnomAD v.2.1.0 and 4.3&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup> in v.4.1.0, with no Finnish carriers.</p><p>Following a comprehensive germline analysis of 19 genes linked to UM tumorigenesis, BAP1, or RCC in this large consecutive series of Finnish patients with UM, and considering our prior research on <italic toggle="yes">BAP1</italic> and <italic toggle="yes">MBD4</italic> in similar cohorts (Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0045" ref-type="bibr">2020</xref>, <xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>), the present findings affirm <italic toggle="yes">BAP1</italic> as the primary germline contributor to predisposition to UM in Finland. Specifically, pathogenic germline <italic toggle="yes">BAP1</italic> variants were present in 2% of unselected patients and 75% of those with FUM (Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>; Turunen et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0062" ref-type="bibr">2016</xref>), whereas no deleterious variants were detected in <italic toggle="yes">MBD4</italic> (Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0045" ref-type="bibr">2020</xref>). Conversely, 0.4% of patients, as revealed by our study, harbor such variants in <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">MET</italic> genes associated with dominant cancer risk. In one previous study, the frequency of <italic toggle="yes">BRCA1</italic> variants in UM (1/156, 0.64%) was nearer to that of the general population (0.26%) (Abdel&#x02010;Rahman et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0003" ref-type="bibr">2020</xref>) than in the Finnish population (0.37% vs. 0.056%), while the association of the <italic toggle="yes">MET</italic> variant detected with cancer remains uncertain.</p><p>To the best of our knowledge, two patients with UM have previously been identified with a pathogenic germline <italic toggle="yes">BRCA1</italic> variant. The first one, c.2603C&#x02009;&#x0003e;&#x02009;G, p.(Ser868*), was described in a proband with UM and prostate cancer, along with a family history of lymphoma, breast, stomach, cervical, skin, and liver cancers (Abdel&#x02010;Rahman et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0003" ref-type="bibr">2020</xref>). The second, a deletion spanning exon 20, was identified in a female with UM at 42&#x02009;years of age, followed by breast cancer, and with a familial history of breast cancer (Cruz et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0007" ref-type="bibr">2011</xref>). Previous studies have also implicated <italic toggle="yes">BRCA2</italic> (Cruz et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0007" ref-type="bibr">2011</xref>; Iscovich et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0022" ref-type="bibr">2002</xref>; Sinilnikova et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0057" ref-type="bibr">1999</xref>) and <italic toggle="yes">FLCN (</italic>Fontcuberta et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0013" ref-type="bibr">2011</xref>) in patients with UM. Neither one harbored pathogenic variants in our consecutive cohort of Finnish patients with UM.</p><p>Moreover, the coding regions of six genes associated with UM tumorigenesis (<italic toggle="yes">GNAQ</italic>, <italic toggle="yes">GNA11</italic>, <italic toggle="yes">CYSLTR2</italic>, <italic toggle="yes">PLCB4</italic>, <italic toggle="yes">EIF1AX</italic>, or <italic toggle="yes">SF3B1</italic>) revealed no pathogenic germline variants and they are not expected to predispose to UM. This is consistent with previous studies, which found no pathogenic germline variants in <italic toggle="yes">GNA11</italic> or <italic toggle="yes">GNAQ</italic> in patients with UM (Abdel&#x02010;Rahman et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0002" ref-type="bibr">2011</xref>; Hawkes et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0017" ref-type="bibr">2013</xref>; Onken et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0040" ref-type="bibr">2008</xref>). The hotspot variations R183 and Q209 characteristic of UM are speculated to be incompatible with life (Piaggio et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0042" ref-type="bibr">2019</xref>), supported by observing them only in somatic or mosaic state (Van Trigt, Kelly, and Hughes&#x000a0;<xref rid="pcmr13198-bib-0065" ref-type="bibr">2022</xref>). Similarly, the absence of reports of <italic toggle="yes">CYSLTR2</italic>, <italic toggle="yes">PLCB4</italic>, <italic toggle="yes">SF3B1</italic>, or <italic toggle="yes">EIF1AX</italic> driver variants appearing in the germline, despite tumor analysis utilizing corresponding germline DNA, suggests that such variants are not identified in patients with UM elsewhere either (Field et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0012" ref-type="bibr">2018</xref>; Johansson et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0023" ref-type="bibr">2016</xref>; Nell et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0039" ref-type="bibr">2021</xref>).</p><p>BLM is a DNA helicase and a &#x0201c;caretaker&#x0201d; tumor suppressor, maintaining genomic integrity and preventing DNA damage accumulation (Hickson&#x000a0;<xref rid="pcmr13198-bib-0019" ref-type="bibr">2003</xref>). While carriers of pathogenic germline <italic toggle="yes">BLM</italic> variants do not exhibit a clear cancer risk, the variants likely increase cancer susceptibility when combined with other risk factors. For instance, pathogenic <italic toggle="yes">BLM</italic> variant carriers have lower tolerance to asbestos, leading to increased incidence of mesothelioma, and <italic toggle="yes">BLM</italic> loss is associated with higher frequency of intestinal tumors in Apc<sup>Min</sup> mice (Bononi et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0005" ref-type="bibr">2020</xref>; Cunniff, Bassetti, and Ellis&#x000a0;<xref rid="pcmr13198-bib-0009" ref-type="bibr">2017</xref>; Goss et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0014" ref-type="bibr">2002</xref>; Hickson&#x000a0;<xref rid="pcmr13198-bib-0019" ref-type="bibr">2003</xref>). Thus, <italic toggle="yes">BLM</italic> variants might not predispose to UM but could amplify risk in the presence of coinciding risk factors, whether genetic or environmental. Given that no consistent environmental factors and only a few risk loci in addition to the genes already mentioned have been identified for UM (Mobuchon et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0034" ref-type="bibr">2017</xref>, <xref rid="pcmr13198-bib-0035" ref-type="bibr">2022</xref>; Thomsen et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0060" ref-type="bibr">2020</xref>), it is likely that as yet unidentified risk factors contribute to the variable incidence of UM by ethnicity and latitude (Aronow, Topham, and Singh&#x000a0;<xref rid="pcmr13198-bib-0004" ref-type="bibr">2018</xref>; Kivel&#x000e4;&#x000a0;<xref rid="pcmr13198-bib-0028" ref-type="bibr">2014</xref>) and its familial occurrence (Abdel&#x02010;Rahman et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0003" ref-type="bibr">2020</xref>; Rai et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0044" ref-type="bibr">2017</xref>; Repo et&#x000a0;al.&#x000a0;<xref rid="pcmr13198-bib-0046" ref-type="bibr">2019</xref>).</p><p>Our study has inherent limitations. Without primary tumor biopsies, the causative relationship between each germline variant and UM remains unconfirmed, leaving the possibility of chance association. Additionally, the short&#x02010;read sequencing might not detect large rearrangements or copy&#x02010;number variations, and the 30% VAF cutoff could make low frequency variants to go undetected.</p><p>To conclude, other UM drivers than <italic toggle="yes">BAP1</italic> do not harbor pathogenic germline variants in Finnish patients with UM and are not expected to predispose to UM. Our germline analysis of genes associated with the BAP1 protein did not explain familial UM predisposition. Hence, other genetic factors contributing to UM likely still need to be discovered.</p><sec id="pcmr13198-sec-0004"><title>Ethics Statement</title><p>A written informed consent was obtained from all participants. The project was approved by the institutional review board of the Hospital Region of Helsinki and Uusimaa on June 11, 2012, and it followed the tenets of the Declaration of Helsinki.</p></sec><sec sec-type="COI-statement" id="pcmr13198-sec-0003"><title>Conflicts of Interest</title><p>JAT received lecture fees from Thea Finland and Santen Finland, served in the advisory board of Novartis Finland, and as a consultant for Maculaser Oy and Pixieray Oy. TTK received lecture fees from Santen Finland. All are unrelated to this work. All other authors did not report a conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pcmr13198-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Figure S1.</bold> A List of the 19 genes analyzed and the inclusion criteria. <italic toggle="yes">BAP1</italic> and <italic toggle="yes">MBD4</italic> are included for comparison but not presently analyzed. <bold>B</bold> Export from the String database showing the interrelations of the analyzed genes.</p></caption><media xlink:href="PCMR-38-0-s001.pdf"/></supplementary-material><supplementary-material id="pcmr13198-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>Figure S2.</bold> Representative Integrative Genomics Viewer (IGV) captures of targeted amplicon sequencing reads show identified variants of pathogenic, likely pathogenic and unknown significance. Variant allele frequency (VAF) was calculated from the total sequencing depth (DP) observed in IGV.</p></caption><media xlink:href="PCMR-38-0-s002.pdf"/></supplementary-material></sec></body><back><ack id="pcmr13198-sec-0005"><title>Acknowledgments</title><p>NGS library preparation, sequencing and FIMM Variant Calling Pipeline analysis were performed by the Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki.</p></ack><sec sec-type="data-availability" id="pcmr13198-sec-0007"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="pcmr13198-bibl-0001"><title>References</title><ref id="pcmr13198-bib-0001"><mixed-citation publication-type="journal" id="pcmr13198-cit-0001">
<string-name>
<surname>Abdel&#x02010;Rahman</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pilarski</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ezzat</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Sexton</surname>
</string-name>, and <string-name>
<given-names>F. H.</given-names>
<surname>Davidorf</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>Cancer Family History Characterization in an Unselected Cohort of 121 Patients With Uveal Melanoma</article-title>.&#x0201d; <source>Familial Cancer</source>
<volume>9</volume>, no. <issue>3</issue>: <fpage>431</fpage>&#x02013;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1007/s10689-010-9328-7</pub-id>.<pub-id pub-id-type="pmid">20157784</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0002"><mixed-citation publication-type="journal" id="pcmr13198-cit-0002">
<string-name>
<surname>Abdel&#x02010;Rahman</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pilarski</surname>
</string-name>, <string-name>
<given-names>J. B.</given-names>
<surname>Massengill</surname>
</string-name>, <string-name>
<given-names>B. B.</given-names>
<surname>Christopher</surname>
</string-name>, and <string-name>
<given-names>F. H.</given-names>
<surname>Davidorf</surname>
</string-name>. <year>2011</year>. &#x0201c;<article-title>Lack of GNAQ Germline Mutations in Uveal Melanoma Patients With High Risk for Hereditary Cancer Predisposition</article-title>.&#x0201d; <source>Familial Cancer</source>
<volume>10</volume>, no. <issue>2</issue>: <fpage>319</fpage>&#x02013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1007/s10689-010-9401-2</pub-id>.<pub-id pub-id-type="pmid">21072599</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0003"><mixed-citation publication-type="journal" id="pcmr13198-cit-0003">
<string-name>
<surname>Abdel&#x02010;Rahman</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Sample</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pilarski</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Whole Exome Sequencing Identifies Candidate Genes Associated With Hereditary Predisposition to Uveal Melanoma</article-title>.&#x0201d; <source>Ophthalmology</source>
<volume>127</volume>, no. <issue>5</issue>: <fpage>668</fpage>&#x02013;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1016/j.ophtha.2019.11.009</pub-id>.<pub-id pub-id-type="pmid">32081490</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0004"><mixed-citation publication-type="journal" id="pcmr13198-cit-0004">
<string-name>
<surname>Aronow</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<given-names>A. K.</given-names>
<surname>Topham</surname>
</string-name>, and <string-name>
<given-names>A. D.</given-names>
<surname>Singh</surname>
</string-name>. <year>2018</year>. &#x0201c;<article-title>Uveal Melanoma: 5&#x02010;Year Update on Incidence, Treatment, and Survival (SEER 1973&#x02010;2013)</article-title>.&#x0201d; <source>Ocular Oncology and Pathology</source>
<volume>4</volume>, no. <issue>3</issue>: <fpage>145</fpage>&#x02013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1159/000480640</pub-id>.<pub-id pub-id-type="pmid">29765944</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0005"><mixed-citation publication-type="journal" id="pcmr13198-cit-0005">
<string-name>
<surname>Bononi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Goto</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Ak</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Heterozygous Germline <italic toggle="yes">BLM</italic> Mutations Increase Susceptibility to Asbestos and Mesothelioma</article-title>.&#x0201d; <source>Proceedings of the National Academy of Sciences of the United States of America</source>
<volume>117</volume>, no. <issue>52</issue>: <fpage>33466</fpage>&#x02013;<lpage>33473</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2019652117</pub-id>.<pub-id pub-id-type="pmid">33318203</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0006"><mixed-citation publication-type="journal" id="pcmr13198-cit-0006">
<string-name>
<surname>Carbone</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>H. I.</given-names>
<surname>Pass</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Ak</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations</article-title>.&#x0201d; <source>Journal of Thoracic Oncology</source>
<volume>17</volume>, no. <issue>7</issue>: <fpage>873</fpage>&#x02013;<lpage>889</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2022.03.014</pub-id>.<pub-id pub-id-type="pmid">35462085</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0007"><mixed-citation publication-type="journal" id="pcmr13198-cit-0007">
<string-name>
<surname>Cruz</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Teule</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Caminal</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Blanco</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Piulats</surname>
</string-name>. <year>2011</year>. &#x0201c;<article-title>Uveal Melanoma and <italic toggle="yes">BRCA1/BRCA2</italic> Genes: A Relationship That Needs Further Investigation</article-title>.&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>29</volume>, no. <issue>34</issue>: <fpage>e827</fpage>&#x02013;<lpage>e829</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2011.37.8828</pub-id>.<pub-id pub-id-type="pmid">22025144</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0008"><mixed-citation publication-type="journal" id="pcmr13198-cit-0008">
<string-name>
<surname>Cuddapah</surname>, <given-names>V. A.</given-names>
</string-name>, <string-name>
<given-names>H. A.</given-names>
<surname>Dubbs</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Adang</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Understanding the Phenotypic Spectrum of ASXL&#x02010;Related Disease: Ten Cases and a Review of the Literature</article-title>.&#x0201d; <source>American Journal of Medical Genetics Part A</source>
<volume>185</volume>, no. <issue>6</issue>: <fpage>1700</fpage>&#x02013;<lpage>1711</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.62156</pub-id>.<pub-id pub-id-type="pmid">33751773</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0009"><mixed-citation publication-type="journal" id="pcmr13198-cit-0009">
<string-name>
<surname>Cunniff</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Bassetti</surname>
</string-name>, and <string-name>
<given-names>N. A.</given-names>
<surname>Ellis</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition</article-title>.&#x0201d; <source>Molecular Syndromology</source>
<volume>8</volume>, no. <issue>1</issue>: <fpage>4</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1159/000452082</pub-id>.<pub-id pub-id-type="pmid">28232778</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0010"><mixed-citation publication-type="journal" id="pcmr13198-cit-0010">
<string-name>
<surname>Derrien</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Rodrigues</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Eeckhoutte</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Germline <italic toggle="yes">MBD4</italic> Mutations and Predisposition to Uveal Melanoma</article-title>.&#x0201d; <source>Journal of the National Cancer Institute</source>
<volume>113</volume>, no. <issue>1</issue>: <fpage>80</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djaa047</pub-id>.<pub-id pub-id-type="pmid">32239153</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0011"><mixed-citation publication-type="journal" id="pcmr13198-cit-0011">
<string-name>
<surname>Dompmartin</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>C. J. M.</given-names>
<surname>van der Vleuten</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Dekeuleneer</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>GNA11&#x02010;Mutated Sturge&#x02010;Weber Syndrome Has Distinct Neurological and Dermatological Features</article-title>.&#x0201d; <source>European Journal of Neurology</source>
<volume>29</volume>, no. <issue>10</issue>: <fpage>3061</fpage>&#x02013;<lpage>3070</lpage>. <pub-id pub-id-type="doi">10.1111/ene.15452</pub-id>.<pub-id pub-id-type="pmid">35715928</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0012"><mixed-citation publication-type="journal" id="pcmr13198-cit-0012">
<string-name>
<surname>Field</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Durante</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Anbunathan</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Punctuated Evolution of Canonical Genomic Aberrations in Uveal Melanoma</article-title>.&#x0201d; <source>Nature Communications</source>
<volume>9</volume>, no. <issue>1</issue>: <fpage>116</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-017-02428-w</pub-id>.</mixed-citation></ref><ref id="pcmr13198-bib-0013"><mixed-citation publication-type="journal" id="pcmr13198-cit-0013">
<string-name>
<surname>Fontcuberta</surname>, <given-names>I. C.</given-names>
</string-name>, <string-name>
<given-names>D. R.</given-names>
<surname>Salomao</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Quiram</surname>
</string-name>, and <string-name>
<given-names>J. S.</given-names>
<surname>Pulido</surname>
</string-name>. <year>2011</year>. &#x0201c;<article-title>Choroidal Melanoma and lid Fibrofoliculomas in Birt&#x02010;Hogg&#x02010;Dube Syndrome</article-title>.&#x0201d; <source>Ophthalmic Genetics</source>
<volume>32</volume>, no. <issue>3</issue>: <fpage>143</fpage>&#x02013;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.3109/13816810.2010.544367</pub-id>.<pub-id pub-id-type="pmid">21401403</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0014"><mixed-citation publication-type="journal" id="pcmr13198-cit-0014">
<string-name>
<surname>Goss</surname>, <given-names>K. H.</given-names>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Risinger</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Kordich</surname>
</string-name>, et&#x000a0;al. <year>2002</year>. &#x0201c;<article-title>Enhanced Tumor Formation in Mice Heterozygous for Blm Mutation</article-title>.&#x0201d; <source>Science</source>
<volume>297</volume>, no. <issue>5589</issue>: <fpage>2051</fpage>&#x02013;<lpage>2053</lpage>. <pub-id pub-id-type="doi">10.1126/science.1074340</pub-id>.<pub-id pub-id-type="pmid">12242442</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0015"><mixed-citation publication-type="journal" id="pcmr13198-cit-0015">
<string-name>
<surname>Gupta</surname>, <given-names>M. P.</given-names>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Lane</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>DeAngelis</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations</article-title>.&#x0201d; <source>JAMA Ophthalmology</source>
<volume>133</volume>, no. <issue>8</issue>: <fpage>881</fpage>&#x02013;<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2015.1119</pub-id>.<pub-id pub-id-type="pmid">25974357</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0016"><mixed-citation publication-type="journal" id="pcmr13198-cit-0016">
<string-name>
<surname>Hajkova</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Hojny</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Nemejcova</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Germline Mutation in the <italic toggle="yes">TP53</italic> Gene in Uveal Melanoma</article-title>.&#x0201d; <source>Scientific Reports</source>
<volume>8</volume>, no. <issue>1</issue>: <fpage>7618</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-26040-0</pub-id>.<pub-id pub-id-type="pmid">29769598</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0017"><mixed-citation publication-type="journal" id="pcmr13198-cit-0017">
<string-name>
<surname>Hawkes</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Campbell</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Garvin</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Cannon&#x02010;Albright</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Cassidy</surname>
</string-name>, and <string-name>
<given-names>S. A.</given-names>
<surname>Leachman</surname>
</string-name>. <year>2013</year>. &#x0201c;<article-title>Lack of GNAQ and GNA11 Germ&#x02010;Line Mutations in Familial Melanoma Pedigrees With Uveal Melanoma or Blue Nevi</article-title>.&#x0201d; <source>Frontiers in Oncology</source>
<volume>3</volume>: <elocation-id>160</elocation-id>. <pub-id pub-id-type="doi">10.3389/fonc.2013.00160</pub-id>.<pub-id pub-id-type="pmid">23825798</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0018"><mixed-citation publication-type="journal" id="pcmr13198-cit-0018">
<string-name>
<surname>Hearle</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<given-names>B. E.</given-names>
<surname>Damato</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Humphreys</surname>
</string-name>, et&#x000a0;al. <year>2003</year>. &#x0201c;<article-title>Contribution of Germline Mutations in <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">P16</italic>
<sup>
<italic toggle="yes">INK4A</italic>
</sup>, <italic toggle="yes">P14</italic>
<sup>
<italic toggle="yes">ARF</italic>
</sup> and <italic toggle="yes">P15</italic> to Uveal Melanoma</article-title>.&#x0201d; <source>Investigative Ophthalmology &#x00026; Visual Science</source>
<volume>44</volume>, no. <issue>2</issue>: <fpage>458</fpage>&#x02013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.02-0026</pub-id>.<pub-id pub-id-type="pmid">12556369</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0019"><mixed-citation publication-type="journal" id="pcmr13198-cit-0019">
<string-name>
<surname>Hickson</surname>, <given-names>I. D.</given-names>
</string-name>
<year>2003</year>. &#x0201c;<article-title>RecQ Helicases: Caretakers of the Genome</article-title>.&#x0201d; <source>Nature Reviews. Cancer</source>
<volume>3</volume>, no. <issue>3</issue>: <fpage>169</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1012</pub-id>.<pub-id pub-id-type="pmid">12612652</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0020"><mixed-citation publication-type="journal" id="pcmr13198-cit-0020">
<string-name>
<surname>Howles</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Gorvin</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Cranston</surname>
</string-name>, et&#x000a0;al. <year>2023</year>. &#x0201c;<article-title>GNA11 Variants Identified in Patients With Hypercalcemia or Hypocalcemia</article-title>.&#x0201d; <source>Journal of Bone and Mineral Research</source>
<volume>38</volume>, no. <issue>6</issue>: <fpage>907</fpage>&#x02013;<lpage>917</lpage>. <pub-id pub-id-type="doi">10.1002/jbmr.4803</pub-id>.<pub-id pub-id-type="pmid">36970776</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0021"><mixed-citation publication-type="journal" id="pcmr13198-cit-0021">
<string-name>
<surname>Huang</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<given-names>R. J.</given-names>
<surname>Mashl</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wu</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Pathogenic Germline Variants in 10,389 Adult Cancers</article-title>.&#x0201d; <source>Cell</source>
<volume>173</volume>, no. <issue>2</issue>: <fpage>355</fpage>&#x02013;<lpage>370 e314</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.03.039</pub-id>.<pub-id pub-id-type="pmid">29625052</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0022"><mixed-citation publication-type="journal" id="pcmr13198-cit-0022">
<string-name>
<surname>Iscovich</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Abdulrazik</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Cour</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fischbein</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Pe'er</surname>
</string-name>, and <string-name>
<given-names>D. E.</given-names>
<surname>Goldgar</surname>
</string-name>. <year>2002</year>. &#x0201c;<article-title>Prevalence of the <italic toggle="yes">BRCA2</italic> 6174 del T Mutation in Israeli Uveal Melanoma Patients</article-title>.&#x0201d; <source>International Journal of Cancer</source>
<volume>98</volume>, no. <issue>1</issue>: <fpage>42</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.10155</pub-id>.<pub-id pub-id-type="pmid">11857383</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0023"><mixed-citation publication-type="journal" id="pcmr13198-cit-0023">
<string-name>
<surname>Johansson</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>L. G.</given-names>
<surname>Aoude</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Wadt</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Deep Sequencing of Uveal Melanoma Identifies a Recurrent Mutation in PLCB4</article-title>.&#x0201d; <source>Oncotarget</source>
<volume>7</volume>, no. <issue>4</issue>: <fpage>4624</fpage>&#x02013;<lpage>4631</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.6614</pub-id>.<pub-id pub-id-type="pmid">26683228</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0024"><mixed-citation publication-type="journal" id="pcmr13198-cit-0024">
<string-name>
<surname>Johansson</surname>, <given-names>P. A.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Brooks</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Newell</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Whole Genome Landscapes of Uveal Melanoma Show an Ultraviolet Radiation Signature in Iris Tumours</article-title>.&#x0201d; <source>Nature Communications</source>
<volume>11</volume>, no. <issue>1</issue>: <fpage>2408</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-16276-8</pub-id>.</mixed-citation></ref><ref id="pcmr13198-bib-0025"><mixed-citation publication-type="journal" id="pcmr13198-cit-0025">
<string-name>
<surname>Johansson</surname>, <given-names>P. A.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Stark</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Palmer</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Prolonged Stable Disease in a Uveal Melanoma Patient With Germline <italic toggle="yes">MBD4</italic> Nonsense Mutation Treated With Pembrolizumab and Ipilimumab</article-title>.&#x0201d; <source>Immunogenetics</source>
<volume>71</volume>, no. <issue>5&#x02013;6</issue>: <fpage>433</fpage>&#x02013;<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1007/s00251-019-01108-x</pub-id>.<pub-id pub-id-type="pmid">30714079</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0026"><mixed-citation publication-type="journal" id="pcmr13198-cit-0026">
<string-name>
<surname>Kannengiesser</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>M. F.</given-names>
<surname>Avril</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Spatz</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Laud</surname>
</string-name>, <string-name>
<given-names>G. M.</given-names>
<surname>Lenoir</surname>
</string-name>, and <string-name>
<given-names>B.</given-names>
<surname>Bressac&#x02010;de&#x02010;Paillerets</surname>
</string-name>. <year>2003</year>. &#x0201c;<article-title>
<italic toggle="yes">CDKN2A</italic> as a Uveal and Cutaneous Melanoma Susceptibility Gene</article-title>.&#x0201d; <source>Genes, Chromosomes &#x00026; Cancer</source>
<volume>38</volume>, no. <issue>3</issue>: <fpage>265</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1002/gcc.10286</pub-id>.<pub-id pub-id-type="pmid">14506702</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0027"><mixed-citation publication-type="journal" id="pcmr13198-cit-0027">
<string-name>
<surname>Karczewski</surname>, <given-names>K. J.</given-names>
</string-name>, <string-name>
<given-names>L. C.</given-names>
<surname>Francioli</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Tiao</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>The Mutational Constraint Spectrum Quantified From Variation in 141,456 Humans</article-title>.&#x0201d; <source>Nature</source>
<volume>581</volume>, no. <issue>7809</issue>: <fpage>434</fpage>&#x02013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id>.<pub-id pub-id-type="pmid">32461654</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0028"><mixed-citation publication-type="book" id="pcmr13198-cit-0028">
<string-name>
<surname>Kivel&#x000e4;</surname>, <given-names>T.</given-names>
</string-name>
<year>2014</year>. &#x0201c;<part-title>Incidence, Prevalence and Epidemiology of Ocular Melanoma</part-title>, <part-title>Incidence, Prevalence and Epidemiology of Ocular Melanoma</part-title>.&#x0201d; In <source>Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies</source>, <fpage>20</fpage>&#x02013;<lpage>38</lpage>. <publisher-loc>London</publisher-loc>: <publisher-name>Future Medicine Ltd</publisher-name>.</mixed-citation></ref><ref id="pcmr13198-bib-0029"><mixed-citation publication-type="journal" id="pcmr13198-cit-0029">
<string-name>
<surname>Kopanos</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Tsiolkas</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kouris</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>VarSome: The Human Genomic Variant Search Engine</article-title>.&#x0201d; <source>Bioinformatics</source>
<volume>35</volume>, no. <issue>11</issue>: <fpage>1978</fpage>&#x02013;<lpage>1980</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty897</pub-id>.<pub-id pub-id-type="pmid">30376034</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0030"><mixed-citation publication-type="journal" id="pcmr13198-cit-0030">
<string-name>
<surname>Kury</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Ebstein</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Molle</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Rare Germline Heterozygous Missense Variants in BRCA1&#x02010;Associated Protein 1, BAP1, Cause a Syndromic Neurodevelopmental Disorder</article-title>.&#x0201d; <source>American Journal of Human Genetics</source>
<volume>109</volume>, no. <issue>2</issue>: <fpage>361</fpage>&#x02013;<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2021.12.011</pub-id>.<pub-id pub-id-type="pmid">35051358</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0031"><mixed-citation publication-type="journal" id="pcmr13198-cit-0031">
<string-name>
<surname>Li</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Zhi</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Liu</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>MetaRNN: Differentiating Rare Pathogenic and Rare Benign Missense SNVs and InDels Using Deep Learning</article-title>.&#x0201d; <source>Genome Medicine</source>
<volume>14</volume>, no. <issue>1</issue>: <fpage>115</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-022-01120-z</pub-id>.<pub-id pub-id-type="pmid">36209109</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0032"><mixed-citation publication-type="journal" id="pcmr13198-cit-0032">
<string-name>
<surname>Lobo</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Pinto</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Freitas</surname>
</string-name>, et&#x000a0;al. <year>2017</year>. &#x0201c;<article-title>Ovarian Metastasis From Uveal Melanoma With MLH1/PMS2 Protein Loss in a Patient With Germline <italic toggle="yes">MLH1</italic> Mutated Lynch Syndrome: Consequence or Coincidence?</article-title>&#x0201d; <source>Virchows Archiv</source>
<volume>470</volume>, no. <issue>3</issue>: <fpage>347</fpage>&#x02013;<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1007/s00428-016-2052-4</pub-id>.<pub-id pub-id-type="pmid">27915441</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0033"><mixed-citation publication-type="journal" id="pcmr13198-cit-0033">
<string-name>
<surname>Micol</surname>, <given-names>J. B.</given-names>
</string-name>, and <string-name>
<given-names>O.</given-names>
<surname>Abdel&#x02010;Wahab</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>The Role of Additional Sex Combs&#x02010;Like Proteins in Cancer</article-title>.&#x0201d; <source>Cold Spring Harbor Perspectives in Medicine</source>
<volume>6</volume>, no. <issue>10</issue>: <elocation-id>a026526</elocation-id>. <pub-id pub-id-type="doi">10.1101/cshperspect.a026526</pub-id>.<pub-id pub-id-type="pmid">27527698</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0034"><mixed-citation publication-type="journal" id="pcmr13198-cit-0034">
<string-name>
<surname>Mobuchon</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Battistella</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bardel</surname>
</string-name>, et&#x000a0;al. <year>2017</year>. &#x0201c;<article-title>A GWAS in Uveal Melanoma Identifies Risk Polymorphisms in the CLPTM1L Locus</article-title>.&#x0201d; <source>NPJ Genomic Medicine</source>
<volume>2</volume>: <elocation-id>5</elocation-id>. <pub-id pub-id-type="doi">10.1038/s41525-017-0008-5</pub-id>.<pub-id pub-id-type="pmid">28781888</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0035"><mixed-citation publication-type="journal" id="pcmr13198-cit-0035">
<string-name>
<surname>Mobuchon</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Derrien</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Houy</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Different Pigmentation Risk Loci for High&#x02010;Risk Monosomy 3 and low&#x02010;Risk Disomy 3 Uveal Melanomas</article-title>.&#x0201d; <source>Journal of the National Cancer Institute</source>
<volume>114</volume>, no. <issue>2</issue>: <fpage>302</fpage>&#x02013;<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djab167</pub-id>.<pub-id pub-id-type="pmid">34424336</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0036"><mixed-citation publication-type="journal" id="pcmr13198-cit-0036">
<string-name>
<surname>Moore</surname>, <given-names>A. R.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Ceraudo</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Sher</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Recurrent Activating Mutations of G&#x02010;Protein&#x02010;Coupled Receptor CYSLTR2 in Uveal Melanoma</article-title>.&#x0201d; <source>Nature Genetics</source>
<volume>48</volume>, no. <issue>6</issue>: <fpage>675</fpage>&#x02013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3549</pub-id>.<pub-id pub-id-type="pmid">27089179</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0037"><mixed-citation publication-type="journal" id="pcmr13198-cit-0037">
<string-name>
<surname>Nabil</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>El Shafei</surname>
</string-name>, <string-name>
<given-names>N. M.</given-names>
<surname>El Shakankiri</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>A Familial PLCB4 Mutation Causing Auriculocondylar Syndrome 2 With Variable Severity</article-title>.&#x0201d; <source>European Journal of Medical Genetics</source>
<volume>63</volume>, no. <issue>6</issue>: <elocation-id>103917</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.ejmg.2020.103917</pub-id>.<pub-id pub-id-type="pmid">32201334</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0038"><mixed-citation publication-type="journal" id="pcmr13198-cit-0038">
<string-name>
<surname>Nathan</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Palmer</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Johansson</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Loss&#x02010;Of&#x02010;Function Variants in <italic toggle="yes">POT1</italic> Predispose to Uveal Melanoma</article-title>.&#x0201d; <source>Journal of Medical Genetics</source>
<volume>58</volume>, no. <issue>4</issue>: <fpage>234</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2020-107098</pub-id>.<pub-id pub-id-type="pmid">32907878</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0039"><mixed-citation publication-type="journal" id="pcmr13198-cit-0039">
<string-name>
<surname>Nell</surname>, <given-names>R. J.</given-names>
</string-name>, <string-name>
<given-names>N. V.</given-names>
<surname>Menger</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Versluis</surname>
</string-name>, et&#x000a0;al. <year>2021</year>. &#x0201c;<article-title>Involvement of Mutant and Wild&#x02010;Type CYSLTR2 in the Development and Progression of Uveal Nevi and Melanoma</article-title>.&#x0201d; <source>BMC Cancer</source>
<volume>21</volume>, no. <issue>1</issue>: <fpage>164</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-021-07865-x</pub-id>.<pub-id pub-id-type="pmid">33588787</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0040"><mixed-citation publication-type="journal" id="pcmr13198-cit-0040">
<string-name>
<surname>Onken</surname>, <given-names>M. D.</given-names>
</string-name>, <string-name>
<given-names>L. A.</given-names>
<surname>Worley</surname>
</string-name>, <string-name>
<given-names>M. D.</given-names>
<surname>Long</surname>
</string-name>, et&#x000a0;al. <year>2008</year>. &#x0201c;<article-title>Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma</article-title>.&#x0201d; <source>Investigative Ophthalmology &#x00026; Visual Science</source>
<volume>49</volume>, no. <issue>12</issue>: <fpage>5230</fpage>&#x02013;<lpage>5234</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.08-2145</pub-id>.<pub-id pub-id-type="pmid">18719078</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0041"><mixed-citation publication-type="journal" id="pcmr13198-cit-0041">
<string-name>
<surname>Palles</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>H. D.</given-names>
<surname>West</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Chew</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>Germline MBD4 Deficiency Causes a Multi&#x02010;Tumor Predisposition Syndrome</article-title>.&#x0201d; <source>American Journal of Human Genetics</source>
<volume>109</volume>, no. <issue>5</issue>: <fpage>953</fpage>&#x02013;<lpage>960</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2022.03.018</pub-id>.<pub-id pub-id-type="pmid">35460607</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0042"><mixed-citation publication-type="journal" id="pcmr13198-cit-0042">
<string-name>
<surname>Piaggio</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Tozzo</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bernardi</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Secondary Somatic Mutations in G&#x02010;Protein&#x02010;Related Pathways and Mutation Signatures in Uveal Melanoma</article-title>.&#x0201d; <source>Cancers (Basel)</source>
<volume>11</volume>, no. <issue>11</issue>: <elocation-id>1688</elocation-id>. <pub-id pub-id-type="doi">10.3390/cancers11111688</pub-id>.<pub-id pub-id-type="pmid">31671564</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0043"><mixed-citation publication-type="book" id="pcmr13198-cit-0043">
<string-name>
<surname>Pilarski</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>M. I.</given-names>
<surname>Carlo</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Cebulla</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Abdel&#x02010;Rahman</surname>
</string-name>. <year>1993</year>. &#x0201c;<part-title>
<italic toggle="yes">BAP1</italic> Tumor Predisposition Syndrome</part-title>.&#x0201d; In <source>GeneReviews(R)</source>, edited by <person-group person-group-type="editor">
<string-name>
<given-names>M. P.</given-names>
<surname>Adam</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>J.</given-names>
<surname>Feldman</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>G. M.</given-names>
<surname>Mirzaa</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>R. A.</given-names>
<surname>Pagon</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>S. E.</given-names>
<surname>Wallace</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>L. J. H.</given-names>
<surname>Bean</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>K. W.</given-names>
<surname>Gripp</surname>
</string-name>
</person-group>, and <person-group person-group-type="editor">
<string-name>
<given-names>A.</given-names>
<surname>Amemiya</surname>
</string-name>
</person-group>. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>.</mixed-citation></ref><ref id="pcmr13198-bib-0044"><mixed-citation publication-type="journal" id="pcmr13198-cit-0044">
<string-name>
<surname>Rai</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pilarski</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Boru</surname>
</string-name>, et&#x000a0;al. <year>2017</year>. &#x0201c;<article-title>Germline <italic toggle="yes">BAP1</italic> alterations in familial uveal melanoma</article-title>.&#x0201d; <source>Genes, Chromosomes &#x00026; Cancer</source>
<volume>56</volume>, no. <issue>2</issue>: <fpage>168</fpage>&#x02013;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1002/gcc.22424</pub-id>.<pub-id pub-id-type="pmid">27718540</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0045"><mixed-citation publication-type="journal" id="pcmr13198-cit-0045">
<string-name>
<surname>Repo</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>J&#x000e4;ntti</surname>
</string-name>, <string-name>
<given-names>R. S.</given-names>
<surname>J&#x000e4;rvinen</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Germline Loss&#x02010;Of&#x02010;Function Variants in <italic toggle="yes">MBD4</italic> Are Rare in Finnish Patients With Uveal Melanoma</article-title>.&#x0201d; <source>Pigment Cell &#x00026; Melanoma Research</source>
<volume>33</volume>, no. <issue>5</issue>: <fpage>756</fpage>&#x02013;<lpage>762</lpage>. <pub-id pub-id-type="doi">10.1111/pcmr.12892</pub-id>.<pub-id pub-id-type="pmid">32421892</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0046"><mixed-citation publication-type="journal" id="pcmr13198-cit-0046">
<string-name>
<surname>Repo</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>R. S.</given-names>
<surname>J&#x000e4;rvinen</surname>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>J&#x000e4;ntti</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Population&#x02010;Based Analysis of <italic toggle="yes">BAP1</italic> Germline Variations in Patients With Uveal Melanoma</article-title>.&#x0201d; <source>Human Molecular Genetics</source>
<volume>28</volume>, no. <issue>14</issue>: <fpage>2415</fpage>&#x02013;<lpage>2426</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddz076</pub-id>.<pub-id pub-id-type="pmid">31058963</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0047"><mixed-citation publication-type="journal" id="pcmr13198-cit-0047">
<string-name>
<surname>Richards</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Aziz</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bale</surname>
</string-name>, et&#x000a0;al. <year>2015</year>. &#x0201c;<article-title>Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>.&#x0201d; <source>Genetics in Medicine</source>
<volume>17</volume>, no. <issue>5</issue>: <fpage>405</fpage>&#x02013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>.<pub-id pub-id-type="pmid">25741868</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0048"><mixed-citation publication-type="journal" id="pcmr13198-cit-0048">
<string-name>
<surname>Robertson</surname>, <given-names>A. G.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Shih</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Yau</surname>
</string-name>, et&#x000a0;al. <year>2017</year>. &#x0201c;<article-title>Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma</article-title>.&#x0201d; <source>Cancer Cell</source>
<volume>32</volume>, no. <issue>2</issue>: <fpage>204</fpage>&#x02013;<lpage>220 e215</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2017.07.003</pub-id>.<pub-id pub-id-type="pmid">28810145</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0049"><mixed-citation publication-type="journal" id="pcmr13198-cit-0049">
<string-name>
<surname>Robinson</surname>, <given-names>J. T.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Thorvaldsdottir</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Winckler</surname>
</string-name>, et&#x000a0;al. <year>2011</year>. &#x0201c;<article-title>Integrative Genomics Viewer</article-title>.&#x0201d; <source>Nature Biotechnology</source>
<volume>29</volume>, no. <issue>1</issue>: <fpage>24</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1754</pub-id>.</mixed-citation></ref><ref id="pcmr13198-bib-0050"><mixed-citation publication-type="journal" id="pcmr13198-cit-0050">
<string-name>
<surname>Rodrigues</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Mobuchon</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Houy</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations</article-title>.&#x0201d; <source>Clinical Cancer Research</source>
<volume>25</volume>, no. <issue>18</issue>: <fpage>5513</fpage>&#x02013;<lpage>5524</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1215</pub-id>.<pub-id pub-id-type="pmid">31227496</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0051"><mixed-citation publication-type="journal" id="pcmr13198-cit-0051">
<string-name>
<surname>Rodrigues</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Mobuchon</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Houy</surname>
</string-name>, et&#x000a0;al. <year>2018</year>. &#x0201c;<article-title>Outlier Response to Anti&#x02010;PD1 in Uveal Melanoma Reveals Germline <italic toggle="yes">MBD4</italic> Mutations in Hypermutated Tumors</article-title>.&#x0201d; <source>Nature Communications</source>
<volume>9</volume>, no. <issue>1</issue>: <fpage>1866</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-04322-5</pub-id>.</mixed-citation></ref><ref id="pcmr13198-bib-0052"><mixed-citation publication-type="journal" id="pcmr13198-cit-0052">
<string-name>
<surname>Royer&#x02010;Bertrand</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Torsello</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Rimoldi</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>Comprehensive Genetic Landscape of Uveal Melanoma by Whole&#x02010;Genome Sequencing</article-title>.&#x0201d; <source>American Journal of Human Genetics</source>
<volume>99</volume>, no. <issue>5</issue>: <fpage>1190</fpage>&#x02013;<lpage>1198</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.09.008</pub-id>.<pub-id pub-id-type="pmid">27745836</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0053"><mixed-citation publication-type="journal" id="pcmr13198-cit-0053">
<string-name>
<surname>Saint&#x02010;Ghislain</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Derrien</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Geoffrois</surname>
</string-name>, et&#x000a0;al. <year>2022</year>. &#x0201c;<article-title>MBD4 Deficiency Is Predictive of Response to Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma Patients</article-title>.&#x0201d; <source>European Journal of Cancer</source>
<volume>173</volume>: <fpage>105</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2022.06.033</pub-id>.<pub-id pub-id-type="pmid">35863105</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0054"><mixed-citation publication-type="journal" id="pcmr13198-cit-0054">
<string-name>
<surname>Sarantaus</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Huusko</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Eerola</surname>
</string-name>, et&#x000a0;al. <year>2000</year>. &#x0201c;<article-title>Multiple Founder Effects and Geographical Clustering of <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> Families in Finland</article-title>.&#x0201d; <source>European Journal of Human Genetics</source>
<volume>8</volume>, no. <issue>10</issue>: <fpage>757</fpage>&#x02013;<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5200529</pub-id>.<pub-id pub-id-type="pmid">11039575</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0055"><mixed-citation publication-type="journal" id="pcmr13198-cit-0055">
<string-name>
<surname>Shain</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Bagger</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Yu</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>The Genetic Evolution of Metastatic Uveal Melanoma</article-title>.&#x0201d; <source>Nature Genetics</source>
<volume>51</volume>, no. <issue>7</issue>: <fpage>1123</fpage>&#x02013;<lpage>1130</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-019-0440-9</pub-id>.<pub-id pub-id-type="pmid">31253977</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0056"><mixed-citation publication-type="journal" id="pcmr13198-cit-0056">
<string-name>
<surname>Singla</surname>, <given-names>N.</given-names>
</string-name>
<year>2020</year>. &#x0201c;<article-title>Uveal Melanoma and Kidney Cancer: More Similar Than Meets the eye</article-title>.&#x0201d; <source>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</source>
<volume>18</volume>, no. <issue>2</issue>: <fpage>61</fpage>. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/32765803" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/pubmed/32765803</ext-link>.<pub-id pub-id-type="pmid">32765803</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0057"><mixed-citation publication-type="journal" id="pcmr13198-cit-0057">
<string-name>
<surname>Sinilnikova</surname>, <given-names>O. M.</given-names>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Egan</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Quinn</surname>
</string-name>, et&#x000a0;al. <year>1999</year>. &#x0201c;<article-title>Germline brca2 Sequence Variants in Patients With Ocular Melanoma</article-title>.&#x0201d; <source>International Journal of Cancer</source>
<volume>82</volume>, no. <issue>3</issue>: <fpage>325</fpage>&#x02013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1097-0215(19990730)82:3&#x0003c;325::aid-ijc3&#x0003e;3.0.co;2-g</pub-id>.<pub-id pub-id-type="pmid">10399947</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0058"><mixed-citation publication-type="journal" id="pcmr13198-cit-0058">
<string-name>
<surname>Sondka</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bamford</surname>
</string-name>, <string-name>
<given-names>C. G.</given-names>
<surname>Cole</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>Ward</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Dunham</surname>
</string-name>, and <string-name>
<given-names>S. A.</given-names>
<surname>Forbes</surname>
</string-name>. <year>2018</year>. &#x0201c;<article-title>The COSMIC Cancer Gene Census: Describing Genetic Dysfunction Across all Human Cancers</article-title>.&#x0201d; <source>Nature Reviews. Cancer</source>
<volume>18</volume>, no. <issue>11</issue>: <fpage>696</fpage>&#x02013;<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-018-0060-1</pub-id>.<pub-id pub-id-type="pmid">30293088</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0059"><mixed-citation publication-type="journal" id="pcmr13198-cit-0059">
<string-name>
<surname>Szklarczyk</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Gable</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Lyon</surname>
</string-name>, et&#x000a0;al. <year>2019</year>. &#x0201c;<article-title>STRING v11: Protein&#x02010;Protein Association Networks With Increased Coverage, Supporting Functional Discovery in Genome&#x02010;Wide Experimental Datasets</article-title>.&#x0201d; <source>Nucleic Acids Research</source>
<volume>47</volume>, no. <issue>D1</issue>: <fpage>D607</fpage>&#x02013;<lpage>D613</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id>.<pub-id pub-id-type="pmid">30476243</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0060"><mixed-citation publication-type="journal" id="pcmr13198-cit-0060">
<string-name>
<surname>Thomsen</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Chattopadhyay</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Hoffmann</surname>
</string-name>, et&#x000a0;al. <year>2020</year>. &#x0201c;<article-title>Genome&#x02010;Wide Study on Uveal Melanoma Patients Finds Association to DNA Repair Gene TDP1</article-title>.&#x0201d; <source>Melanoma Research</source>
<volume>30</volume>, no. <issue>2</issue>: <fpage>166</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1097/CMR.0000000000000641</pub-id>.<pub-id pub-id-type="pmid">31626034</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0061"><mixed-citation publication-type="journal" id="pcmr13198-cit-0061">
<string-name>
<surname>Tovar</surname>, <given-names>E. A.</given-names>
</string-name>, and <string-name>
<given-names>C. R.</given-names>
<surname>Graveel</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>MET in Human Cancer: Germline and Somatic Mutations</article-title>.&#x0201d; <source>Annals of Translational Medicine</source>
<volume>5</volume>, no. <issue>10</issue>: <fpage>205</fpage>. <pub-id pub-id-type="doi">10.21037/atm.2017.03.64</pub-id>.<pub-id pub-id-type="pmid">28603720</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0062"><mixed-citation publication-type="journal" id="pcmr13198-cit-0062">
<string-name>
<surname>Turunen</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Markkinen</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Wilska</surname>
</string-name>, et&#x000a0;al. <year>2016</year>. &#x0201c;<article-title>
<italic toggle="yes">BAP1</italic> Germline Mutations in Finnish Patients With Uveal Melanoma</article-title>.&#x0201d; <source>Ophthalmology</source>
<volume>123</volume>, no. <issue>5</issue>: <fpage>1112</fpage>&#x02013;<lpage>1117</lpage>. <pub-id pub-id-type="doi">10.1016/j.ophtha.2016.01.008</pub-id>.<pub-id pub-id-type="pmid">26876698</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0063"><mixed-citation publication-type="journal" id="pcmr13198-cit-0063">
<string-name>
<surname>Van Raamsdonk</surname>, <given-names>C. D.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Bezrookove</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Green</surname>
</string-name>, et&#x000a0;al. <year>2009</year>. &#x0201c;<article-title>Frequent Somatic Mutations of GNAQ in Uveal Melanoma and Blue Naevi</article-title>.&#x0201d; <source>Nature</source>
<volume>457</volume>, no. <issue>7229</issue>: <fpage>599</fpage>&#x02013;<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1038/nature07586</pub-id>.<pub-id pub-id-type="pmid">19078957</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0064"><mixed-citation publication-type="journal" id="pcmr13198-cit-0064">
<string-name>
<surname>Van Raamsdonk</surname>, <given-names>C. D.</given-names>
</string-name>, <string-name>
<given-names>K. G.</given-names>
<surname>Griewank</surname>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Crosby</surname>
</string-name>, et&#x000a0;al. <year>2010</year>. &#x0201c;<article-title>Mutations in GNA11 in Uveal Melanoma</article-title>.&#x0201d; <source>New England Journal of Medicine</source>
<volume>363</volume>, no. <issue>23</issue>: <fpage>2191</fpage>&#x02013;<lpage>2199</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1000584</pub-id>.<pub-id pub-id-type="pmid">21083380</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0065"><mixed-citation publication-type="journal" id="pcmr13198-cit-0065">
<string-name>
<surname>Van Trigt</surname>, <given-names>W. K.</given-names>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Kelly</surname>
</string-name>, and <string-name>
<given-names>C. C. W.</given-names>
<surname>Hughes</surname>
</string-name>. <year>2022</year>. &#x0201c;<article-title>GNAQ Mutations Drive Port Wine Birthmark&#x02010;Associated Sturge&#x02010;Weber Syndrome: A Review of Pathobiology, Therapies, and Current Models</article-title>.&#x0201d; <source>Frontiers in Human Neuroscience</source>
<volume>16</volume>: <elocation-id>1006027</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnhum.2022.1006027</pub-id>.<pub-id pub-id-type="pmid">36405075</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0066"><mixed-citation publication-type="journal" id="pcmr13198-cit-0066">
<string-name>
<surname>Virgili</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Gatta</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ciccolallo</surname>
</string-name>, et&#x000a0;al. <year>2007</year>. &#x0201c;<article-title>Incidence of Uveal Melanoma in Europe</article-title>.&#x0201d; <source>Ophthalmology</source>
<volume>114</volume>, no. <issue>12</issue>: <fpage>2309</fpage>&#x02013;<lpage>2315</lpage>. <pub-id pub-id-type="doi">10.1016/j.ophtha.2007.01.032</pub-id>.<pub-id pub-id-type="pmid">17498805</pub-id>
</mixed-citation></ref><ref id="pcmr13198-bib-0067"><mixed-citation publication-type="journal" id="pcmr13198-cit-0067">
<string-name>
<surname>Wang</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Hakonarson</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>ANNOVAR: Functional Annotation of Genetic Variants From High&#x02010;Throughput Sequencing Data</article-title>.&#x0201d; <source>Nucleic Acids Research</source>
<volume>38</volume>, no. <issue>16</issue>: <elocation-id>e164</elocation-id>. <pub-id pub-id-type="doi">10.1093/nar/gkq603</pub-id>.<pub-id pub-id-type="pmid">20601685</pub-id>
</mixed-citation></ref></ref-list></back></article>